C07K 14/68
Melanocyte-stimulating hormone [msh]
Official title: Melanocyte-stimulating hormone [MSH]
C07K14/68 (Melanocyte-stimulating hormone [msh]) appears on 175 US grants and 211 published applications in this corpus.
Search patents in C07K- Granted patents
- 175
- Published applications
- 211
- Assignees
- 99
- Inventors
- 297
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 3 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 9 | 0 |
| 1999 | 3 | 0 |
| 2000 | 4 | 0 |
| 2001 | 2 | 1 |
| 2002 | 2 | 7 |
| 2003 | 5 | 6 |
| 2004 | 4 | 9 |
| 2005 | 5 | 12 |
| 2006 | 4 | 6 |
| 2007 | 6 | 7 |
| 2008 | 5 | 17 |
| 2009 | 4 | 11 |
| 2010 | 3 | 10 |
| 2011 | 6 | 5 |
| 2012 | 1 | 12 |
| 2013 | 12 | 7 |
| 2014 | 7 | 9 |
| 2015 | 7 | 10 |
| 2016 | 11 | 9 |
| 2017 | 11 | 12 |
| 2018 | 5 | 14 |
| 2019 | 10 | 10 |
| 2020 | 5 | 9 |
| 2021 | 7 | 7 |
| 2022 | 6 | 6 |
| 2023 | 4 | 3 |
| 2024 | 4 | 3 |
| 2025 | 3 | 4 |
| 2026 | 2 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers16 Jun 2026US 12,655,178 B2Rhythm Pharmaceuticals, Inc.
- Recombinant protein comprising multiple multi-peptide sets, pharmaceutical composition comprising the recombinant protein, and method for preparing the recombinant protein13 Jan 2026US 12,522,642 B2
- Conjugation of MCR1 ligand with cytotoxic drugs for treating skin cancer14 Oct 2025US 12,440,570 B2Arizona Board of Regents on Behalf of the University of Arizona
- Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages20 May 2025US 12,303,555 B2Nanyang Technological University
- Method of treating melanocortin-4 receptor pathway-associated disorders1 Apr 2025US 12,263,202 B2Rhythm Pharmaceuticals, Inc.
- Melanocortin receptor ligands modified with hydantoin1 Oct 2026US 2026/0297130 A1Ipsen Pharma S.A.S.
- Engineered nucleic acids and methods of use thereof6 Aug 2026US 2026/0224664 A1Moderna TX, Inc.
- Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers11 Jun 2026US 2026/0159543 A1Rhythm Pharmaceuticals, Inc.
- Compositions for the treatment of disease4 Jun 2026US 2026/0151434 A1SightStream Biotherapeutics, Inc.
- Methods of stimulating appetite and/or increasing body weight using non-naturally occurring melanocortin receptor antagonist analogs9 Apr 2026US 2026/0098072 A1Endevica Bio, Inc.
Most cited
By later US patents
- Engineered nucleic acids and methods of use thereof372US 8,822,663 B2Moderna Therapeutics, Inc. · 2014
- DNA sequencing by mass spectrometry via exonuclease degradation235US 6,074,823 ASequenom, Inc. · 2000
- Peptides having potent antagonist and agonist bioactivities at melanocortin receptors102US 5,731,408 AArizona Board of Regents on Behalf of the University of Arizona · 1998
- Hybrid protein101US 4,675,382 APresident and Fellows of Harvard College · 1987
- Compositions and methods for the diagnosis and treatment of psychogenic erectile dysfunction93US 5,576,290 ACompetitive Technologies, Inc. · 1996